Clinical features and treatment response in patients with immune checkpoint inhibitor associated cholangiopathy
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Morven Cunningham und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Immune mediated biliary injury (ICI-cholangiopathy) is a rare toxicity in patients treated with immune checkpoint inhibitors (ICI) and clinical characteristics, treatment responses and optimal management remain poorly characterised. This study aimed to characterize clinical profiles and treatment response in ICI-cholangiopathy.
Methods
Patients treated with anti-PD-1, PDL-1 or CTLA-4 therapy between January 2010 and December 2025 were included in this retrospective study. Patients with ICI-cholangiopathy were identified from patients with significant elevation in cholestatic liver enzymes (R value
Zitieren
APA
Cunningham, M., Lomboy, A. R., Garcia, E. S., Shepherd, F., Burkes, R., Bradbury, P., & Leighl, N. (2026). Clinical features and treatment response in patients with immune checkpoint inhibitor associated cholangiopathy. Medical Research Archives. https://doi.org/10.18103/mra.2026.0273
Vancouver
Cunningham M, Lomboy AR, Garcia ES, Shepherd F, Burkes R, Bradbury P, et al. Clinical features and treatment response in patients with immune checkpoint inhibitor associated cholangiopathy. Medical Research Archives. 2026. doi:10.18103/mra.2026.0273
BibTeX
@article{Cunningham2026,
author = {Cunningham, Morven and Lomboy, Allyn Rey and Garcia, Enrique Sanz and Shepherd, Frances and Burkes, Ronald and Bradbury, Penelope and Leighl, Natasha},
title = {Clinical features and treatment response in patients with immune checkpoint inhibitor associated cholangiopathy},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0273}
}
EUVIMED